A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

NCT04971499 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Dapansutrile
DRUG: Pembrolizumab

Sponsor

April Salama, M.D.

Collaborators

[object Object]
[object Object]